Literature DB >> 2611087

Testing for bimodality in frequency distributions of data suggesting polymorphisms of drug metabolism--histograms and probit plots.

P R Jackson1, G T Tucker, H F Woods.   

Abstract

1. The shape of histograms used to illustrate density distributions of indices of polymorphic drug metabolism was shown to be sensitive to the position of the cell divisions. 2. Non-linearity of the probit plot was shown not to indicate bimodality of the original density distribution. Computer simulation was used to generate examples of unimodal density distributions with curvilinear probit plots. 3. Using the same technique probit plots for bimodal density distributions were constructed. Some were shown to differ less from the probit plots of certain unimodal distributions than did the original density distributions. 4. The position of the antimode was shown not to coincide with inflections seen in the probit plots. 5. A new method for determining the linearity of probit plots is suggested.

Mesh:

Substances:

Year:  1989        PMID: 2611087      PMCID: PMC1380035          DOI: 10.1111/j.1365-2125.1989.tb03557.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  16 in total

1.  ONE CAUSE?MANY CAUSES?THE ARGUMENT FROM THE BIMODAL DISTRIBUTION.

Authors:  E A MURPHY
Journal:  J Chronic Dis       Date:  1964-04

2.  Skewness in commingled distributions.

Authors:  C J Maclean; N E Morton; R C Elston; S Yee
Journal:  Biometrics       Date:  1976-09       Impact factor: 2.571

3.  Polymorphic drug oxidation: pharmacokinetic basis and comparison of experimental indices.

Authors:  P R Jackson; G T Tucker; M S Lennard; H F Woods
Journal:  Br J Clin Pharmacol       Date:  1986-11       Impact factor: 4.335

4.  The influence of enzyme induction on polymorphic sparteine oxidation.

Authors:  M Eichelbaum; S Mineshita; E E Ohnhaus; C Zekorn
Journal:  Br J Clin Pharmacol       Date:  1986-07       Impact factor: 4.335

5.  Enzyme polymorphisms in man.

Authors:  H Harris
Journal:  Proc R Soc Lond B Biol Sci       Date:  1966-03-22

6.  Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man.

Authors:  A Küpfer; R Preisig
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

7.  Polymorphism of theophylline metabolism in man.

Authors:  C A Miller; L B Slusher; E S Vesell
Journal:  J Clin Invest       Date:  1985-05       Impact factor: 14.808

8.  Sparteine oxidation is practically abolished in quinidine-treated patients.

Authors:  R Brinn; K Brøsen; L F Gram; T Haghfelt; S V Otton
Journal:  Br J Clin Pharmacol       Date:  1986-08       Impact factor: 4.335

9.  Debrisoquine polymorphism and the metabolism and action of metoprolol, timolol, propranolol and atenolol.

Authors:  M S Lennard; G T Tucker; J H Silas; H F Woods
Journal:  Xenobiotica       Date:  1986-05       Impact factor: 1.908

10.  Polymorphism of human cytochrome P-450.

Authors:  F P Guengerich; D R Umbenhauer; P F Churchill; P H Beaune; R Böcker; R G Knodell; M V Martin; R S Lloyd
Journal:  Xenobiotica       Date:  1987-03       Impact factor: 1.908

View more
  9 in total

Review 1.  Inborn 'errors' of drug metabolism. Pharmacokinetic and clinical implications.

Authors:  M S Lennard; G T Tucker; H F Woods
Journal:  Clin Pharmacokinet       Date:  1990-10       Impact factor: 6.447

2.  A new, sensitive graphical method for detecting deviations from the normal distribution of drug responses: the NTV plot.

Authors:  L Endrenyi; M Patel
Journal:  Br J Clin Pharmacol       Date:  1991-08       Impact factor: 4.335

3.  Testing for bimodality in frequency distributions of data suggesting polymorphisms of drug metabolism--hypothesis testing.

Authors:  P R Jackson; G T Tucker; H F Woods
Journal:  Br J Clin Pharmacol       Date:  1989-12       Impact factor: 4.335

4.  Evaluation of CYP2D6 phenotype in the Yoruba Nigerian population.

Authors:  Waheed Adeola Adedeji; Sharon Iyobor Igbinoba; Titilayo O Fakeye; Ibrahim Adebayo Oladosu; Fatai Adewale Fehintola; Qing Ma; Gene D Morse
Journal:  Expert Rev Clin Pharmacol       Date:  2017-08-30       Impact factor: 5.045

5.  Phenotypic debrisoquine 4-hydroxylase activity among extensive metabolizers is unrelated to genotype as determined by the Xba-I restriction fragment length polymorphism.

Authors:  J Turgeon; W E Evans; M V Relling; G R Wilkinson; D M Roden
Journal:  Br J Clin Pharmacol       Date:  1991-09       Impact factor: 4.335

6.  Unimodal distribution of the metabolic ratio for debrisoquine in Cuna Amerindians of Panama.

Authors:  L F Jorge; T D Arias; T Inaba; P R Jackson
Journal:  Br J Clin Pharmacol       Date:  1990-08       Impact factor: 4.335

7.  Phenotypic polymorphism and gender-related differences of CYP1A2 activity in a Chinese population.

Authors:  D S Ou-Yang; S L Huang; W Wang; H G Xie; Z H Xu; Y Shu; H H Zhou
Journal:  Br J Clin Pharmacol       Date:  2000-02       Impact factor: 4.335

8.  Nonparametric expectation maximisation (NPEM) population pharmacokinetic analysis of caffeine disposition from sparse data in adult caucasians: systemic caffeine clearance as a biomarker for cytochrome P450 1A2 activity.

Authors:  Dimiter Terziivanov; Kristina Bozhinova; Velislava Dimitrova; Ivanka Atanasova
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

9.  Functional phenotyping of the CYP2D6 probe drug codeine in the horse.

Authors:  S R Gretler; C J Finno; P H Kass; H K Knych
Journal:  BMC Vet Res       Date:  2021-02-13       Impact factor: 2.741

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.